Conditions: Intracranial Meningioma
Keywords: Avastin RAD001 Meningioma Bevacizumab Everolimus Brain
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 18
Healthy volunteers: no

Brief summary:
In this multicenter, Phase II trial, the investigators plan to evaluate the activity of the combination of bevacizumab and everolimus in patients with recurrent, progressive meningioma following maximal treatment with surgical resection and local radiation therapy. Although these patients are relatively rare, there is currently no established standard of treatment for a disease that causes a great deal of morbidity, and that is eventually fatal.

Detailed description:

Arms:
arm 1: Everolimus; this drug will be dosed at 10 mg orally DAILY for the duration of the study.

Bevacizumab; this drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study

Interventions: intervention 1: Everolimus intervention 2: Bevacizumab
Intervention descriptions: intervention 1: This drug will be dosed at 10 mg orally DAILY for the duration of the study. intervention 2: This drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study.

Protocol document: